Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
- Isla, D.
- Lopez-Brea, M.
- Espinosa, M.
- Arrabal, N.
- Pérez-Parente, D.
- Carcedo, D.
- Bernabé-Caro, R.
Journal:
Cost Effectiveness and Resource Allocation
ISSN: 1478-7547
Year of publication: 2023
Volume: 21
Issue: 1
Type: Article